Gritti, Giuseppe http://orcid.org/0000-0002-6789-5123
Ferrari, Silvia
Lussana, Federico
Barbui, Anna Maria
Landi, Francesco
Rondi, Monica
Putelli, Alessandro
Ballardini, Francesco
Quaresmini, Giulia
Paganessi, Muriel
Pavoni, Chiara
Ghirardi, Arianna
Gotti, Elisa
Capelli, Chiara
Golay, Josée
Introna, Martino
Rambaldi, Alessandro
Funding for this research was provided by:
Regione Lombardia (number CP2_10/2018, PLAGENCELL, number CP2_10/2018, PLAGENCELL, number CP2_10/2018, PLAGENCELL)
Associazione Italiana per la Ricerca sul Cancro (ISM project code: 21147, ISM project code: 21147, ISM project code: 21147)
Amgen (Thousand Oaks, CA) Fondazione per la Ricerca Ospedale Maggiore
Article History
Received: 24 February 2024
Revised: 10 April 2024
Accepted: 15 April 2024
First Online: 26 April 2024
Competing interests
: GG reports consultancy fees from Genmab, Roche, Abbvie, Ideogen, Kite-Gilead, Takeda, and travel support from Gilead Kite, Janssen, Beigene. AR reports consultancy fees from Amgen, Pfizer, Novartis, Kite-Gilead, Jazz, Astellas, Abbvie, Incyte, Omeros, Celgene BMS, Sanofi. FL reports consultancy fees from Amgen, Pfizer, Incyte, Bristol Myers Squibb, AbbVie, Clinigen. The other authors declare no competing interests.
: The study was approved by the competing health authority, by the Ethics Committee and was registered with access number NCT03823365. An ancillary biological study was approved to prolong the assessment of immunologic parameters. Patients, or their legal representative, provided written consent to participate in the study.